UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 234

Sortiert nach

Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer

Journal of clinical oncology, 2022-04, Vol.40 (12), p.1301-1311

2022

Volltextzugriff (PDF)

Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer

Journal of clinical oncology, 2020-05, Vol.38 (14), p.1505-1517

2020

Volltextzugriff (PDF)

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

The New England journal of medicine, 2016-11, Vol.375 (19), p.1823-1833

2016

Volltextzugriff (PDF)

Anthracyclines induce early changes in left ventricular systolic and diastolic function: A single centre study

PloS one, 2017-04, Vol.12 (4), p.e0175544

2017

Volltextzugriff (PDF)

Neoadjuvant immunotherapy for non-small cell lung cancer: right drugs, right patient, right time?

Journal for immunotherapy of cancer, 2021-06, Vol.9 (6), p.e002248

2021

Volltextzugriff (PDF)

Pembrolizumab with platinum-based chemotherapy with or without epacadostat as first-line treatment for metastatic non-small cell lung cancer: a randomized, partially double-blind, placebo-controlled phase II study

BMC cancer, 2024-07, Vol.23 (Suppl 1), p.1250-12, Article 1250

2024

Volltextzugriff (PDF)

Physical Activity for Symptom Management in Women With Metastatic Breast Cancer: A Randomized Feasibility Trial on Physical Activity and Breast Metastases

Journal of pain and symptom management, 2019-12, Vol.58 (6), p.929-939

2019

Volltextzugriff (PDF)

Five‐year survival and clinical correlates among patients with advanced non‐small cell lung cancer, melanoma and renal cell carcinoma treated with immune check‐point inhibitors in Australian tertiary oncology centres

Cancer medicine (Malden, MA), 2023-03, Vol.12 (6), p.6788-6801

2023

Volltextzugriff (PDF)

Use of durvalumab in stage III non‐small‐cell lung cancer based on eligibility for the PACIFIC study

Thoracic cancer, 2023-02, Vol.14 (6), p.563-572

2023

Volltextzugriff (PDF)

Interpretation in Consultations With Immigrant Patients With Cancer: How Accurate Is It?

Journal of clinical oncology, 2011-07, Vol.29 (20), p.2801-2807

2011

Volltextzugriff (PDF)

Outcomes With Pembrolizumab Monotherapy in Patients With Programmed Death-Ligand 1–Positive NSCLC With Brain Metastases: Pooled Analysis of KEYNOTE-001, 010, 024, and 042

JTO clinical and research reports, 2021-08, Vol.2 (8), p.100205-100205, Article 100205

2021

Volltextzugriff (PDF)

Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes With Pembrolizumab Plus Chemotherapy Versus Chemotherapy For Metastatic NSCLC

JTO clinical and research reports, 2023-01, Vol.4 (1), p.100431-100431, Article 100431

2023

Volltextzugriff (PDF)

Simplified phenotyping of CYP2D6 for tamoxifen treatment using the N-desmethyl-tamoxifen/ endoxifen ratio

Breast (Edinburgh), 2020-12, Vol.54, p.229-234

2020

Volltextzugriff (PDF)

Occult metastatic thyroid cancer diagnosed during breast cancer axillary sentinel node biopsy

Endocrinology, diabetes & metabolism case reports, 2020-08, Vol.2020 (1), p.1-6

2020

Volltextzugriff (PDF)

Cyclin D1, EMS1 and 11q13 amplification in breast cancer

Breast cancer research and treatment, 2003-04, Vol.78 (3), p.323-335

2003

Volltextzugriff (PDF)

Abstract CT075: KEYNOTE-189: Randomized, double-blind, phase 3 study of pembrolizumab (pembro) or placebo plus pemetrexed (pem) and platinum as first-line therapy for metastatic NSCLC

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.CT075-CT075

2018

Volltextzugriff (PDF)

Symptomatic Pneumonitis With Durvalumab After Concurrent Chemoradiotherapy in Unresectable Stage III NSCLC

JTO clinical and research reports, 2024-03, Vol.5 (3), p.100638-100638, Article 100638

2024

Volltextzugriff (PDF)

Phase 2 study of pembrolizumab (pembro) monotherapy for previously treated metastatic triple-negative breast cancer (mTNBC): KEYNOTE-086 cohort A

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.1008-1008

2017

Volltextzugriff (PDF)

Management of Early Breast Cancer at an Australian Cancer Centre During the Early Phase of COVID-19 Pandemic

Archives of breast cancer, 2021-11, p.318-328

2021

Volltextzugriff (PDF)

Ribociclib (LEE011) and letrozole in estrogen receptor-positive (ER+), HER2-negative (HER2–) advanced breast cancer (aBC): Phase Ib safety, preliminary efficacy and molecular analysis

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.568-568

2016

Volltextzugriff (PDF)

364 KRAS mutations in patients with nonsquamous non–small-cell lung cancer: prevalence and relationship with PD-L1 expression, tumor mutation burden and smoking status

Journal for immunotherapy of cancer, 2021-11, Vol.9 (Suppl 2), p.A391-A391

2021

Volltextzugriff (PDF)

Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater

Journal of clinical oncology, 2019-03, Vol.37 (7), p.537-546

2019

Volltextzugriff (PDF)

Pembrolizumab for Early Triple-Negative Breast Cancer

The New England journal of medicine, 2020-02, Vol.382 (9), p.810-821

2020

Volltextzugriff (PDF)

1 – 25 von 234

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(222)
Mit Volltextzugriff
(227)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(131)
Life Sciences & Biomedicine
(118)
Humans
(85)
Female
(60)
Oncology
(59)
Middle Aged
(42)
Adult
(37)
Aged
(33)
Male
(33)
Patients
(26)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(23)
Lung Neoplasms - Drug Therapy
(23)
Chemotherapy
(22)
Immunotherapy
(22)
Aged, 80 And Over
(21)
Tumors
(21)
Cancer Therapies
(20)
Breast Cancer
(19)
Lung Cancer
(19)
Metastasis
(18)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(5)

Menü

Weitere Dienste

Einstellungen

Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer

Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

Anthracyclines induce early changes in left ventricular systolic and diastolic function: A single centre study

Neoadjuvant immunotherapy for non-small cell lung cancer: right drugs, right patient, right time?

Pembrolizumab with platinum-based chemotherapy with or without epacadostat as first-line treatment for metastatic non-small cell lung cancer: a randomized, partially double-blind, placebo-controlled phase II study

Physical Activity for Symptom Management in Women With Metastatic Breast Cancer: A Randomized Feasibility Trial on Physical Activity and Breast Metastases

Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies

Five‐year survival and clinical correlates among patients with advanced non‐small cell lung cancer, melanoma and renal cell carcinoma treated with immune check‐point inhibitors in Australian tertiary oncology centres

Use of durvalumab in stage III non‐small‐cell lung cancer based on eligibility for the PACIFIC study

Interpretation in Consultations With Immigrant Patients With Cancer: How Accurate Is It?

A phase 2, multicenter, open-label study of anti-LAG-3 ieramilimab in combination with anti-PD-1 spartalizumab in patients with advanced solid malignancies

Outcomes With Pembrolizumab Monotherapy in Patients With Programmed Death-Ligand 1–Positive NSCLC With Brain Metastases: Pooled Analysis of KEYNOTE-001, 010, 024, and 042

Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes With Pembrolizumab Plus Chemotherapy Versus Chemotherapy For Metastatic NSCLC

Simplified phenotyping of CYP2D6 for tamoxifen treatment using the N-desmethyl-tamoxifen/ endoxifen ratio

Occult metastatic thyroid cancer diagnosed during breast cancer axillary sentinel node biopsy

Cyclin D1, EMS1 and 11q13 amplification in breast cancer

Abstract CT075: KEYNOTE-189: Randomized, double-blind, phase 3 study of pembrolizumab (pembro) or placebo plus pemetrexed (pem) and platinum as first-line therapy for metastatic NSCLC

Symptomatic Pneumonitis With Durvalumab After Concurrent Chemoradiotherapy in Unresectable Stage III NSCLC

Phase 2 study of pembrolizumab (pembro) monotherapy for previously treated metastatic triple-negative breast cancer (mTNBC): KEYNOTE-086 cohort A

Management of Early Breast Cancer at an Australian Cancer Centre During the Early Phase of COVID-19 Pandemic

Ribociclib (LEE011) and letrozole in estrogen receptor-positive (ER+), HER2-negative (HER2–) advanced breast cancer (aBC): Phase Ib safety, preliminary efficacy and molecular analysis

364 KRAS mutations in patients with nonsquamous non–small-cell lung cancer: prevalence and relationship with PD-L1 expression, tumor mutation burden and smoking status

Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater

Pembrolizumab for Early Triple-Negative Breast Cancer

Suchergebnisse filtern